This is the authors' abstract. We don't add key points for this paper.
In this data set, twice daily prazosin substantially reduced not only nightmares and sleep disruption, but the majority of hyperarousal symptoms, with some evidence of efficacy for avoidance symptoms. The relationship of baseline symptom distribution to which symptoms showed significant response to prazosin reinforces the possibility that differences in a clinical trial's participant populations may significantly influence trial outcome. The pattern of symptom endorsement at the level of individual subjects was consistent with prazosin-responsive items sharing a common pathophysiologic mechanism.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hendrickson et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: